Objective: To observe the clinical effect of targeted perfusion with DSA-guided bronchoscope in the treatment of multidrug-resistant pulmonary tuberculosis (MDR-TB). Methods: A total of 188 patients with multidrug-resistant pulmonary tuberculosis (MDR-TB) who were hospitalized for treatment between September 2023 and September 2024 were included. After random division, 94 cases were included in the control group and received systemic anti-tuberculosis chemotherapy; 94 patients were included in the treatment group. Based on digital subtraction angiography (DSA), targeted drugs were injected into the bronchoscope cavity to complete anti-tuberculosis treatment. The sputum and imaging changes were observed in both groups. Results: The sputum negative rate of the treatment group was significantly higher than that of the control group (86.2%; 70.2%) (u = 2.74, P < 0.01). The absorption rate of CT image lesion (significant absorption + partial absorption) was significantly higher than that of control group (83.0%; 50%) (u = 2.45, P < 0.05). The closure rate of chest CT cavity was significantly higher than that of control group (74.2%; 39.1%) (u = 2.20, P < 0.05). The improvement rate of clinical symptoms in the treatment group was statistically higher than that in the control group. There was no significant difference in the incidence of adverse reactions between the two groups (x = 0.434, P > 0.05). Conclusion: Based on inclusion in 20DSA, infusion of targeted drugs into bronchoscopy can significantly improve disease efficacy, with mild adverse reactions that patients can tolerate, and is worthy of promotion and application.
World Health Organization, 2024, Global Tuberculosis Report 2024. https://www.who.int/publications/i/item/9789240101531.
Technical Guidance Group of the Fifth National Epidemiological Sampling Survey of Tuberculosis in China, 2012, Report on the Fifth National Epidemiological Sampling Survey of Tuberculosis. Chinese Journal of Antituberculosis, 31: 485–508.
World Health Organization, 2023, Global Tuberculosis Report 2023. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023.
Zhang X, Hu C, Chen S, et al., 2011, Research on Interventional Therapy for MDR-TB. Journal of Clinical Pulmonary Medicine, 16: 62–64.
Fu Y, Chu N, Fan S, et al., 2008, The Role of Interventional Therapy in the Comprehensive Treatment of MDR-TB. Chinese Journal of Tuberculosis and Respiratory Diseases, 31: 95–98.
National Tuberculosis Control Academic Conference, 1982, Evaluation of the Efficacy of Chemotherapy for Pulmonary Tuberculosis. Chinese Journal of Tuberculosis and Respiratory Diseases, 5(6): 383.
Zhu L, 2010, New Progress in the Treatment of Drug-Resistant and Multidrug-Resistant Tuberculosis. Chinese Journal of Medicine, 45(12): 3–8.
Zeng H, Wu W, 2015, Current Status and Progress in Diagnosis and Treatment of Drug-Resistant Tuberculosis. Journal of Clinical Pulmonary Medicine, 20(10): 1880–1882.
Tang S, Gao W, 2011, Clinical Tuberculosis. Beijing: People’s Health Publishing House, China.
Cai G, Yu H, 2013, Current Status and Research Progress of Extensively Drug-Resistant Tuberculosis. Chinese Journal of Practical Medicine, 8(35): 231–232.